Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

mirxes
TO KNOW. TO ACT.

Mirxes Holding Company Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2629)

VOLUNTARY ANNOUNCEMENT
MEMORANDUM OF UNDERSTANDING WITH APOLLO

This announcement is made by Mirxes Holding Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business development of the Group.

MEMORANDUM OF UNDERSTANDING

The board (the "**Board**") of directors (the "**Director(s)**") of the Company announces that the Company has entered into a memorandum of understanding (the "**MOU**") with Apollo Health and Lifestyle Limited ("**AHLL**"), the wholly owned subsidiary of Apollo Hospitals Enterprise Limited ("**Apollo**"), to explore a strategic collaboration to co-develop and commercialize advanced cancer early detection solutions in India and neighboring countries. Subject to the fulfilment of the agreed objectives, and respective board approvals, a joint venture company is expected to be founded in India with an equity value of not less than US$50 million based on the intellectual properties, clinical pipelines, research and development, clinical testing infrastructure and commercial channels to be injected by the Company and Apollo.

INFORMATION OF APOLLO

Apollo and AHLL stand as the preeminent healthcare providers in Asia, recognized globally for its advanced care across South Asia and the Middle East, and is committed to enhancing its stature as a global leader in preventive oncology and disease management. Apollo is also distinguished as India's foremost cancer care provider and is dedicated to becoming a pivotal player in the global arena of early disease detection and prevention through innovative methodologies.

STRATEGIC RATIONALE

The collaboration brings together Mirxes' breakthrough miRNA and multi-omics technologies, core products GASTROClear and LUNGClear, and its maturing clinical pipeline of colorectal, liver, breast cancers and CADENCE multi-cancer tests, with Apollo's extensive clinical expertise, nationwide hospital network and community-based healthcare delivery capabilities, to achieve a bold vision: to detect cancer earlier, intervene when it can be cured, and transform outcomes for millions of patients.

The collaboration is intended to facilitate the commercialisation and market adoption of these solutions at scale, thereby expanding access to early disease screening across the region.

SCOPE OF THE COLLABORATION

The key collaborative areas as set out in the MOU are as follows:

(a) subject to the fulfilment of the agreed objectives, respective board approvals, and execution of the definitive agreement, to form an equity joint venture company to co-develop, validate and commercialize advanced cancer early detection solutions and other molecular diagnostic innovations in India and its neighboring countries. It is envisaged that AHLL shall hold a majority equity stake while the Company holds a significant minority stake;

(b) the joint venture company shall license the intellectual property of and products from the Company for commercialization in India, on such terms as may be mutually agreed between Parties in the definitive Agreement;

(c) the joint venture company shall explore expanding beyond cancer detection into other preventive and precision healthcare diagnostics, utilizing AI and data-driven analytics for new test developments for specialties such as cardiology and transplants;

(d) the joint venture company shall market and sell cancer early detection tests through Apollo's vast healthcare infrastructures, including but not limited to Apollo's health screening facilities, pharmacy establishments, and digital health platforms; and

(e) the joint venture company shall cultivate strategic alliances with other leading biopsy and genomic cancer companies to solidify a global presence.

The term of the MOU ends on November 18, 2026.

The Board is also of the view that the proposed strategic partnership with Apollo represents a significant and synergistic opportunity that is aligned with the Group's long-term strategic objectives. The collaboration is intended to facilitate broader access to the Group's diagnostic solutions for early cancer detection, leveraging Apollo's extensive network of hospitals and substantial patient volumes, thereby addressing existing gaps within the healthcare delivery system in India, particularly in relation to early diagnosis and disease screening. The Board further considers that this partnership may serve as a scalable platform for the Group's future expansion across India, contributing to earlier clinical intervention and improved patient outcomes.

Shareholders and potential investors of the Company should note that the collaboration under the MOU may or may not proceed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that GASTROClear™ will ultimately be successfully commercialized at scale by the Company, and we may not be able to ultimately develop and market LUNGClear™ as an IVD product, or ultimately develop and market any or all of our six product candidates, successfully.

By Order of the Board
Mirxes Holding Company Limited
Dr. ZHOU Lihan
Executive Director and Chief Executive Officer

Hong Kong, February 26, 2026

As at the date of this announcement, the Board comprises (i) Dr. ZHOU Lihan and Dr. ZOU Ruiyang as executive Directors; (ii) Dr. TOO Heng Phon, Dr. LE Beilin and Mr. LIU Da as non-executive Directors; and (iii) Dr. LAM Sin Lai Judy, Mr. FANG Xiao and Ms. MA Andrea Lo Ling as independent non-executive Directors.